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See Editorial, pages 5–6Background & Aims:We determined the optimal HCV treatment
prioritization strategy for interferon-free (IFN-free) HCV direct-
with reduced drug costs or varied sustained virological
response/duration by genotype/fibrosis stage.acting antivirals (DAAs) by disease stage and risk status incorpo-
rating treatment of people who inject drugs (PWID).
Methods: A dynamic HCV transmission and progression model
compared the cost-effectiveness of treating patients early vs.
delaying until cirrhosis for patients with mild or moderate fibro-
sis, where PWID chronic HCV prevalence was 20, 40 or 60%.
Treatment duration was 12 weeks at £3300/wk, to achieve a
95% sustained viral response and was varied by genotype/stage
in alternative scenarios. We estimated long-term health costs
(in £UK = €1.3 = $1.5) and outcomes as quality adjusted life-
years (QALYs) gained using a £20,000 willingness to pay per QALY
threshold. We ranked strategies with net monetary benefit
(NMB); negative NMB implies delay treatment.
Results: The most cost-effective group to treat were PWID with
moderate fibrosis (mean NMB per early treatment
£60,640/£23,968 at 20/40% chronic prevalence, respectively), fol-
lowed by PWID with mild fibrosis (NMB £59,258 and £19,421,
respectively) then ex-PWID/non-PWID with moderate fibrosis
(NMB £9,404). Treatment of ex-PWID/non-PWID with mild fibro-
sis could be delayed (NMB -£3,650). In populations with 60%
chronic HCV among PWID it was only cost-effective to prioritize
DAAs to ex-PWID/non-PWID with moderate fibrosis. For every
one PWID in the 20% chronic HCV setting, 2 new HCV infections
were averted. One extra HCV-related death was averted per 13
people with moderate disease treated. Rankings were unchangedJournal of Hepatology 20
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Chronic infection with hepatitis C virus (HCV) is a leading cause
of morbidity and mortality across the world. Globally, an esti-
mated 80–150 million people are chronically infected with HCV,
which if left untreated can lead to cirrhosis, liver cancer, and
death [1,2]. In high-income countries, people who inject drugs
(PWID) are the main risk group for HCV transmission, contribut-
ing to >90% of new infections in settings such as the UK [3].
Effective antiviral treatments for HCV can result in a sustained
virological response (SVR, equating to a cure) in the large major-
ity of people [4]. HCV antiviral treatment could also be a key
component in preventing HCV transmission through the reduc-
tion of chronic HCV prevalence among PWID [5–7]. Previous
research has indicated that treating PWID with interferon (IFN)-
containing therapy (i.e., pegylated interferon (PegIFN) and rib-
avirin (RBV)) is likely to be more cost-effective than treating
non- or former-PWID with no ongoing risk behavior due to the
substantial potential prevention benefit [8]. Current HCV treat-
ment rates in many countries, however, are insufficient to reduce
either the rise in end stage liver disease (ESLD) [9,10] or HCV
transmission [11].
The HCV antiviral treatment landscape is rapidly changing.
SVR rates with new IFN-free direct-acting antivirals (DAAs) are
higher than for PegIFN + RBV: at >90% for all genotypes compared16 vol. 65 j 17–25
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to <50% for genotype 1 and up to 80% for genotype 3 [4]. Crucially,
IFN-free DAA treatment has improved SVR in people with geno-
type 1 cirrhosis from 30% to >80% [12,13]. IFN-free DAAs are
highly tolerable, oral-only, shorter duration (12–24 weeks) and
will likely involve once daily regimens. These new therapies are
associated, however, with considerable treatment costs (e.g.,
$60,000–80,000 per 12 week course).
Although some new DAA agents have been deemed cost-
effective in the UK [14] and are reimbursable in the US and Aus-
tralia, there is heated debate as to how best to prioritize patients
for treatment [15,16]. International guidelines in 2014 suggest
prioritizing IFN-free DAA therapy for patients with advanced liver
disease [17,18]. A recent analysis from the United States demon-
strated that IFN-free DAA treatment among people with mild
stages of fibrosis (F0 or F1) is not cost-effective compared to
delaying treatment until more moderate stages of fibrosis (F2)
[19]. However, these recommendations are based on expected
individual patient-level benefit in reduced progression to ESLD,
and neglect potential prevention benefits to the population due
to the impact on HCV transmission [16].
We therefore use a dynamic model of HCV transmission
among PWID, combined with data on disease progression, and
treatment to determine the more cost-effective strategy for prior-
itizing HCV antiviral treatment after diagnosis.Methods
Mathematical model
An existing dynamic cost-effectiveness model of HCV transmission, disease pro-
gression, and treatment was adapted [8] (Supplementary Fig. 1). The model incor-
porated HCV transmission among PWID, such that HCV infection and reinfection
was related to the background prevalence of chronic infection among PWID,
which could change over time. The model included the risk of reinfection after
treatment for PWID, and also the population benefits of reducing onward trans-
mission. We used the model to examine three chronic HCV prevalence settings
among PWID (20%, 40% and 60%) at baseline. This corresponded to baseline inci-
dences of infection/reinfection among PWID of 4% (2.5–97.5% Confidence Interval
(95% CI) 3–5%), 9% (95% CI 7–13%), and 21% (95% CI 15–30%), in the 20%, 40%, and
60% chronic prevalence scenarios, respectively. The model was open, with PWIDs
entering the population on initiation of injecting and were tracked after perma-
nent cessation of injecting when they were assumed to be no longer at risk of
reinfection or transmission.
The model was a deterministic, compartmental model which was stratified
by risk status (PWID, former-PWID), HCV genotype (genotype 1 and 4, genotype
2, and genotype 3) and infection status and disease stage (never infected or
infected and spontaneously cleared, mild HCV, moderate HCV, compensated cir-
rhosis [CC], decompensated cirrhosis [DC], hepatocellular carcinoma [HCC], liver
transplant, post-transplant). For simplicity, we assumed an individual had one
dominant genotype strain which affected treatment SVR, and that an individual’s
risk of acquiring a specific genotype was related to the circulating prevalence of
each genotype. Additionally, for those stages eligible for antiviral treatment (mild
HCV, moderate HCV, and compensated cirrhosis), the model was further stratified
by treatment status (never treated, on treatment, SVR, non-SVR). Those who
achieved SVR were at risk of reinfection; we assumed no change in risk behavior
after treatment, so each individual’s risk of reinfection was equal to that of pri-
mary infection. We assumed that those with mild or moderate fibrosis who
achieved SVR were at no risk of further liver disease progression unless they were
reinfected. Based on clinical evidence, we assumed that those with compensated
cirrhosis who achieved SVR remained at elevated risk of disease progression due
to existing liver damage [20,21]. Individuals who did not attain SVR proceeded
through the natural history of liver disease progression and were assumed to
be ineligible for retreatment, as no drugs are currently licensed for retreatment
of IFN-free DAA failures. The base-case assumed the risk of transmission or acqui-
sition of HCV was independent of disease stage or duration of injecting, as evi-
dence is unclear whether, apart from the first year, injecting risk increases or
decreases over the course of an injecting career.18 Journal of Hepatology 20Antiviral treatment scenarios
We explored three antiviral treatment scenarios to assess whether differences in
the characteristics of the treatment course affected the prioritization strategy.
1. Future IFN-free DAA scenario: IFN-free DAAs for 12 weeks with 95% SVR for
all disease stages and genotypes [4,22–24]. We used this scenario as the
base-case for most of our analyses.
2. ‘Current’ DAA scenario: IFN-free DAAs with 90–95% SVR for mild/moderate
HCV, and 70–90% SVR for compensated cirrhosis depending on genotype.
Treatment durations are 8–12 weeks (genotypes 1 and 2) and 24 weeks
(genotype 3).
3. ‘Current’ DAA scenario except PegIFN/RBV for mild G3: As in scenario (2) but
with PegIFN/RBV for mild genotype 3.
Assumptions regarding SVR and treatment durations, and costs for different
HCV antiviral treatment regimes can be found in Table 1. As future costs of many
IFN-free regimens are not yet determined, we assumed a weekly drug cost of
£3300 per week (cost of sofosbuvir + ledipasvir [25]). Treatment delivery costs
assumed are £90 per week [26] for ex/non-PWID, PWID delivery is 120% of
non/ex-PWID cost [8]. Treatment delivery costs included the costs of staff time
and tests/investigations; we assumed higher treatment delivery costs for PWID
due to additional staff time and psychiatric assessments as in previous economic
evaluations [8,27,28]. In the sensitivity analysis, we varied the SVR by disease
stage and genotype, cost, and treatment duration.Prioritization analysis using cost-effectiveness methods
For each level of chronic HCV prevalence in PWID (20%, 40% and 60%), we com-
pared the following treatment options to assess the most cost-effective prioritiza-
tion strategy:Baseline
Treat everyone with compensated cirrhosis (mainly ex-PWIDwith no ongoing risk
so have very little ‘treatment as prevention’ benefit) every year.We chose this base-
line to represent current guidance and the real-world prioritization of treating indi-
viduals with advanced disease (CC) first.We did not treat individuals with DC, HCC,
or post-transplant, as treatment for these groups is recommended on a case-by-
case basis and disease progression outcomes are still uncertain; individuals who
are not in these stages at baselinewere all treated at the CC stage upon progression.
Intervention
In addition to baseline treatment of all those with CC, we modeled treating, in
addition, each year for the next 10 years:
 1 PWID (in our population of 1000 PWID) at the mild stage
 1 PWID (in our population of 1000 PWID) at the moderate stage
 1 non or ex injector at the mild stage
 1 non or ex injector at the moderate stage
As shown in previous work including population-level treatment as preven-
tion benefits [8,27], the cost-effectiveness of treatment was strongly dependent
on the treatment rate. The higher the treatment rate for PWID, the greater the
prevention benefits, and therefore the greater the cost-effectiveness of treatment
for PWID. Therefore, we conservatively examined a very low treatment rate
among PWID because HCV treatment rates among PWID are extremely low in
the UK and most other global settings (<1% PWID per year) and so it does not
overly bias towards treatment of PWID.
We calculated the costs and quality adjusted life-years (QALYs) for a further
40 years, giving a total time horizon of 50 years.
The cost-effectiveness analysis used a UK health care provider perspective.
Costs were valued in 2014 UK pounds (£1 = €1.3 = $1.50 USD) and health out-
comes were expressed in QALYs. Both costs and health utilities were discounted
at 3.5% per annum in the base-case according to UK National Institute for Health
and Care Excellence (NICE) guidelines [29].
Uncertainty in the underlying parameters was accounted for, such that
epidemiological parameters, disease transition probabilities, costs, and health ben-
efits were analysed using multivariate random sampling from appropriate distri-
butions. For each of the 1,000 sampled parameter sets, we simulated three
chronic HCV baseline prevalence scenarios among PWID at equilibrium,which rep-
resented the range of prevalence observed across most sites in Europe and other16 vol. 65 j 17–25
Table 1. Model assumptions regarding antiviral treatment sustained viral response (SVR) rates for the different treatment scenarios examined.
Treatment Mild/moderate (F0-F3) 
SVR
Comp. cirrhosis 
(F4) SVR
Treatment duration Weekly cost 
(2014 GBP £)
Future IFN-free DAA scenario
IFN-free DAA all genotypes 0.95 0.95 12 weeks £3300 drug + delivery*
‘Current’ IFN-free DAA scenario
IFN-free DAA G1 0.95 0.90 8 weeks non-cirrhotic, 12 
weeks comp. cirrhosis 
£3300 drug + delivery*
IFN-free DAA G2 0.90 0.90 12 weeks £3300 drug + delivery*
IFN-free DAA G3 0.90 0.70 24 weeks £3300 drug + delivery*
‘Current’ IFN-free DAA scenario (as above) with PegIFN + RBV for G3 mild/moderate
PegIFN + RBV G3 mild/moderate 0.80 - 24 weeks £228 drug + delivery*
⁄As future costs of many IFN-free regimens are not yet determined or known, we assume a weekly cost equal to that of sofosbuvir + ledipasvir (approximately £3300 per
week [25]) but vary this (one-quarter, one-half, and double the baseline cost) in the sensitivity analysis. Treatment delivery costs assumed are £90 per week [26] for ex/non-
PWID, PWID delivery is 120% of non/ex-PWID cost [8]. Treatment delivery costs include the costs of staff time and tests/investigations; we assume higher treatment
delivery costs for PWID due to additional staff time and psychiatric assessments as previous economic evaluations [8,27,28].
JOURNAL OF HEPATOLOGYdeveloped countries, (20%, 40%, and 60%), obtaining matched simulations for each
prevalence setting and treatment scenario. These simulations therefore provided
endemic infection population numbers in each disease category (PWID and
ex/non-PWID) given a total population of 1,000 PWID.
Using the sampled 1,000 simulation sets, we calculated the mean incremental
costs and mean incremental QALYs gained from an intervention treatment strat-
egy compared to delayed treatment until compensated cirrhosis. All those who
were untreated received best supportive care with its associated costs. We then
ranked strategies through calculating the net monetary benefit (NMB) through
the equation NMB = ((mean incremental QALYs willingness to pay threshold)
– mean incremental costs), using £20,000 and £30,000 willingness to pay per
additional QALY (WTP) thresholds for the UK, with the highest rank having the
highest NMB. If strategies were similar in NMB, we assessed the probability that
one is more cost-effective than another using the runs from the probabilistic sen-
sitivity analysis. Patient groups with a negative NBM (<£0) were not prioritized. A
negative NMB implied that treatment should be delayed in the patient group until
a later disease stage – and that treatment at that stage was not cost-effective at a
specific WTP. We also plotted cost-effectiveness efficiency frontiers on the cost-
effectiveness plane; interventions which lie off the frontier were dominated
(more expensive and/or gaining fewer QALYs). Additionally, we presented the
impact on HCV-related mortality, cases of end stage liver disease (decompensated
cirrhosis and HCC), and on new HCV infections. Using the full set of 1,000 prob-
abilistic runs, we utilized one-way sensitivity analyses to test how changes in the
model structure or individual parameter assumptions impact the order in which
the DAAs should be prioritized.
Transition probabilities
HCV natural history disease stage probabilities are shown in Table 2. Based on
HCV progression values, the model predicted 12% [95% CI 7–20%] cirrhosis by
20 years. New PWID entered the model at 20 years old and had an elevated risk
of mortality due to drug-related death during injecting (1% per year [30]), as com-
pared to ex/non-PWID (average lifespan 76 years [31]). PWID permanently
ceased injecting after an average of 11 years (sampled from 6 to 16 years due
to substantial uncertainty in this estimate [32,33]).
Utilities
Health utilities were attached to each disease stage and obtained from previous
UK economic evaluations and the UK mild HCV trial (Table 2). We assumed that
uninfected PWID experience a lower quality of life compared to an uninfected ex/
non-PWID. For the base-case, we further assumed that HCV-infected health util-
ities are comparable between PWID and ex/non-PWID, due to an absence of evi-
dence indicating differences between these populations. This resulted in a smaller
quality of life loss upon HCV infection for PWID, therefore the individual-level
benefit of treating a PWID was less than for a non-injector.
Costs
Health care provider costs for untreated HCV disease stages were taken from pre-
vious economic evaluations and the UK mild HCV trial, and inflated to 2014 GBP
using the Hospital and Community Health Services Pay and Prices Index (Table 2).Journal of Hepatology 20Sensitivity analysis
We performed a multivariate probabilistic uncertainty analysis for the base-case
treatment scenario (‘Future IFN-free DAAs’, 95% SVR) to assess the sensitivity of
the NMB to uncertainty in the underlying parameters. We also performed a num-
ber of one-way sensitivity analyses on the following parameters: time horizon
(20 or 100 years, compared to 50 in base-case), discount rate (0% and 6% dis-
counting, compared to 3.5% in base-case), IFN-free DAA drug costs (at one-
quarter (£825), one-half (£1650), or double (£6600) per week compared to
base-case), PWID SVR rate (reduced by a relative 10% compared to non/ex-IDU
SVR, equal in base-case), SVR with cirrhosis (reduced to 85% from 95% in base-
case), behavior after treatment (50% reduction in risk after treatment compared
to no reduction), average injecting duration (5 or 20 years, compared to a mean
of 11 years in base-case). Additionally, because future costs are uncertain and
likely to reduce over time, we simulated an additional scenario where DAA costs
reduced by 75% in 10 years (from £3300 to £825/week (approximately $1200
USD/week), comparable to the price of sofosbuvir/ledipasvir available in some
low/middle income countries.Results
Prioritizing IFN-free DAAs for all genotypes with 95% SVR
For a 20% and 40% baseline chronic prevalence among PWID, the
most cost-effective prioritization strategy was to target PWID
before ex/non-PWID due to the substantial prevention benefits
of treatment (Table 3, Fig. 1) and early treatment of PWID was
cost-effective under a £20,000 WTP (Table 4, Supplementary
Table 1). Using a £20,000 WTP and in the scenario with 20%
chronic prevalence among PWID, the most cost-effective group
to treat were moderate PWID (mean NMB per additional early
treatment £60,640) in 54% of the simulations and mild PWID in
46% of simulations (mean NMB £59,258). Treatment of mild or
moderate ex/non-PWID dominated (i.e., was more expensive
and results in fewer QALY gains). However, if all PWID were trea-
ted, the next best target group would be ex- or non-injectors with
moderate disease (mean NMB £9,404). Compared to delaying
treatment, treatment of mild ex/non-PWID is not cost-effective
under this WTP (mean NMB -£3,650). Similarly, at 40% chronic
prevalence (Table 3, Fig. 1), targeting PWID was the most cost-
effective strategy, with moderate and mild PWID yielding similar
benefit to each other (mean NMB £23,868 and £19,421 for the
moderate and mild PWID, respectively) but less benefit was
achieved overall than in the 20% prevalence scenario where
greater prevention benefits were accrued (HCV infections
averted).16 vol. 65 j 17–25 19
Table 2. Model parameters for transition rates, health utilities, and disease stage costs.
Mean value Distribution Reference
Transition probabilities per year (all probabilities converted to instantaneous rates)
Mild HCV to moderate HCV 0.025 Beta (α = 38.0859, β = 1485.3516) [26]
Moderate HCV to CC 0.037 Beta (α = 26.905, β = 700.2582) [26]
CC to DC 0.039 Beta (α = 14.6168, β = 360.1732) [26]
CC to DC SVR, relative risk of non-SVR 7% Log normal (95% CI 0.03, 0.20) [20, 45]
CC/DC to HCC 0.014 Beta (α = 1.9326, β = 136.1074) [26]
CC to HCC SVR, relative risk of non-SVR 23% Log normal (95% CI 0.16, 0.35) [20]
DC/HCC to LT 0.03 Beta (α = 6.5256, β = 210.9945) [26]
DC to death 0.13 Beta (α = 147.03, β = 983.97) [26]
HCC to death 0.43 Beta (α = 117.1033, β = 155.23) [26]
LT to death 0.21 Beta (α = 16.2762, β = 61.2294) [26]
Post transplant to death 0.057 Beta (α = 22.9017, β = 378.8825) [26]
Epidemiological parameters
Average lifespan (years) 76 Normal (76,0.06) [31, 46]
Average injecting duration until permanent cessation (years) 11 Uniform (6,16) [32]
Average PWID excess death rate per year 0.01 Poisson [30]
Proportion genotype 1 46% [47]
Proportion genotype 2 11% [47]
Proportion genotype 3 43% [47]
Number new PWID per year Fit to a total population of 1000 PWID
Infection rate per year Fit to give prevalence considered (20/40/60%), corresponding to primary/
reinfection incidences of 4% (95% CI 3-5), 9% (95% CI 7%-13%), and 21% 
(95% CI 15-30%), respectively. 
Health state utilities per year
Ex-PWID 
Uninfected 0.94 [48]
Mild HCV 0.77 Beta (α = 521.2375, β = 155.6943) [26, 49]
Moderate HCV 0.66 Beta (α = 168.2461, β = 86.6723) [26, 49]
Compensated cirrhosis 0.55 Beta (α = 47.1021, β = 38.5381) [26, 49]
Decompensated cirrhosis 0.45 Beta (α = 123.75, β = 151.25) [26, 49]
Hepatocellular carcinoma 0.45 Beta (α = 123.75, β = 151.25) [26, 49]
Liver transplant 0.45 Beta (α = 123.75, β = 151.25) [26, 49]
Post transplant 0.67 Beta (α = 59.2548, β = 29.1852) [49, 50]
Mild HCV SVR 0.82 Beta (α = 65.8678, β = 14.4588) [26, 49]
Moderate HCV SVR 0.72 Beta (α = 58.0608, β = 22.5792) [26, 49, 51]
CC SVR 0.61 Beta (α = 58.0476, β = 37.1124) [50]
Utility decrement on PegIFN/RBV -0.11 [26, 49, 51]
Utility decrement on IFN-free DAAs -0.06 [14]
PWID 
Uninfected 0.85 Uniform (0.8, 0.9) [8]
HCV disease states As in ex-PWID Assumed
Costs (£ per year, except where noted)
Mild diagnosed 178 PPI‡ × Gamma (k = 25.6995, θ = 5.3698) [26, 49]
Moderate diagnosed 925 PPI‡ × Gamma (k = 88.8502, θ = 8.0698) [26, 49]
Cirrhosis diagnosed 1468 PPI‡ × Gamma (k = 24.2342, θ = 46.9584) [26, 49]
Decompensated cirrhosis 11,765 PPI‡ × Gamma (k = 36.0249, θ = 253.1582) [26, 49]
Hepatocellular carcinoma 10,484 PPI‡ × Gamma (k = 18.1081, θ = 448.8045) [26]
Liver transplant (per transplant) 35,256 PPI‡ × Gamma (k = 89.7536, θ = 304.5004) [26]
Cost of care in year of liver transplant 12,201 PPI‡ × Gamma (k = 13.7788, θ = 686.4168) [26]
Post transplant 1787 PPI‡ × Gamma (k = 15.2189, θ = 91.0053) [26]
Mild SVR 334 PPI‡ × Gamma (k = 28.8141, θ = 8.9887) [26]
Moderate SVR 925 PPI‡ × Gamma (k = 88.8502, θ = 8.0698) [26]
Cirrhosis SVR 1468 PPI‡ × Gamma (k = 24.2342, θ = 46.9584) [26]
PPI = Hospital and Community Health Services Pay and Prices Index inflation factor from 03/04 for 13/14 (1.29). CC, compensated cirrhosis; HCC, hepatocellular carcinoma;
LT, liver transplant; SVR, sustained viral response; PegIFN, pegylated interferon; RBV, ribavirin.
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Table 3. Net monetary benefit of prioritizing early IFN-free DAA treatment (95% SVR all genotypes) to different groups compared to delayed treatment until
compensated cirrhosis.
Group Mean net monetary 
benefit per early 
treatment
£20,000 WTP 
(Rank)
Mean net monetary 
benefit per early 
treatment
£30,000 WTP 
(Rank)
Mean new 
infections 
averted per 
early treatment 
(95% CI)
Mean incremental 
HCV deaths 
averted per early 
treatment, 
(95% CI)
Mean incremental 
decompensated 
cirrhosis cases 
averted per early 
treatment (95% CI)
Mean incremental 
HCC cases 
averted per early 
treatment 
(95% CI)
Ex/non-PWID, mild -3650 (NR) 8796 (20% prev: 
4th, 40% prev: 4th, 
60% prev: 3rd)
0 0.03 (0.01-0.05) 0.02 (0.01-0.04) 0.01 (0-0.04)
Ex/non PWID, moderate 9404 (20% prev: 
3rd, 40% prev: 
3rd, 60% prev: 1st)
22,994 (20% prev: 
3rd, 40% prev: 3rd, 
60% prev: 1st)
0 0.08 (0.03-0.17) 0.06 (0.03-0.11) 0.04 (0.01-0.13)
PWID, mild 20% chronic prev 59,258 (2) 97,878 (1) 2.3 (2-2.6) 0.05 (0.02-0.11) 0.04 (0.02-0.07) 0.03 (0-0.09)
PWID, moderate 20% prev 60,640 (1) 96,008 (2) 1.9 (1.6-2.3) 0.09 (0.04-0.18) 0.07 (0.03-0.13) 0.05 (0.01-0.14)
PWID, mild 40% chronic prev 19,421 (2) 41,194 (2) 0.78 (0.75-0.81) 0.03 (0.01-0.07) 0.02 (0.01-0.05) 0.02 (0-0.05)
PWID, moderate 40% prev 23,868 (1) 44,166 (1) 0.66 (0.58-0.73) 0.07 (0.03-0.13) 0.05 (0.02-0.09) 0.03 (0-0.10)
PWID, mild 60% chronic prev -6879 (NR) 3899 (4) 0.23 (0.21-0.24) 0.02 (0.01-0.04) 0.01 (0.01-0.03) 0.01 (0-0.03)
PWID, moderate 60% prev -1326 (NR) 9002 (2) 0.2 (0.17-0.22) 0.04 (0.02-0.08) 0.03 (0.01-0.06) 0.02 (0-0.06)
NR, not ranked as net monetary benefit negative; HCC, hepatocellular carcinoma.
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Fig. 1. Results on the incremental cost-effectiveness plane showing the
efficient frontiers for 20% (solid line), 40% (dashed grey line), and 60% (dashed
black line) chronic prevalence scenarios for the ‘Future IFN-free DAA’
treatment scenario. Results shown for treatment of PWID populations (squares)
and ex-non-injectors (diamonds) with moderate disease (grey squares) and mild
disease (white squares) compared to delayed treatment at the compensated
cirrhosis stage. Treatment scenarios which do not fall on the frontier are
dominated (more expensive with fewer benefits). Costs/QALYs are incremental to
treatment of all those with compensated cirrhosis and best supportive care for all
others.
JOURNAL OF HEPATOLOGYBy contrast, at 60% chronic prevalence (Table 3, Fig. 1, Supple-
mentary Table 1), targeting moderate ex/non-PWID was the only
cost-effective option compared to delaying treatment. In this set-
ting, due to the very high risk of reinfection, treatment of PWID
was not cost-effective compared to delay.
Impact on new HCV infections averted
Treatment of PWID averted the most new infections in the lower
prevalence scenarios; for example at 20% chronic prevalence, 2.3
[95% CI 2–2.6] new HCV infections were averted per early treat-
ment of mild PWID. In the higher prevalence scenarios, fewerJournal of Hepatology 20infections were averted due to higher reinfection rates (treat-
ment of mild PWID averts 0.78 [95% CI 0.75–0.81] and 0.23
[95% CI 0.21–0.24] new HCV infections per early treatment in
the 40% and 60% prevalence scenarios respectively). Treatment
of moderate PWID averted slightly fewer infections due to the
elevated risk of mortality from disease progression.
Impact on HCV mortality and end stage liver disease burden per
treatment
The strategy that had the greatest impact on HCV mortality and
burden of end stage liver disease was treatment of people with
moderate disease (Table 3). Compared to delayed treatment at
cirrhosis, each early treatment of a moderate ex-non-PWID in
the low HCV prevalence setting averted 0.08 HCV deaths (95%
CI 0.03–0.17), 0.06 (95% CI 0.03–0.11) cases of decompensated
cirrhosis, and 0.04 (95% CI 0.01–0.13) cases of HCC over 50 years,
i.e., for every 13 people treated with moderate disease, one HCV-
related death was prevented. ESLD outcomes were similar for
treatment of moderate PWID in prevalence settings below 60%
(Table 3). Early treatment at the mild stage had less impact on
immediate disease outcomes; treating a mild ex-non-PWID
averted 0.03 (95% CI 0.01–0.05) HCV deaths, 0.02 (95% CI 0.01–
0.04) cases of decompensated cirrhosis, and 0.01 (95% CI 0–
0.04) cases of HCC per treatment over 50 years. Treatment of
PWID with moderate disease averted fewer deaths and cases of
ESLD in the 60% prevalence scenarios compared to treatment of
ex/non-PWID due to the immediate risk of reinfection (Table 3).
Alternative DAA treatment scenarios
The prioritization rankings remain unchanged across different
treatment availability scenarios, such as using ‘Current’ DAA
treatments (with lower SVR for cirrhosis and longer treatment
durations for genotype 3), or the ‘Current’ DAA scenario with
IFN/RBV for mild genotype 3 as is currently recommended by
NICE in the UK (Table 4). Therefore, the prioritization rankings
were robust to differences in treatment characteristics across16 vol. 65 j 17–25 21
Table 4. Net monetary benefit using the ‘Current DAA’ treatment scenario and the ‘Current DAA with IFN/RBV for mild genotype 3’ treatment scenarios with a
£20,000 WTP.
Group ‘Future’ DAA scenario, mean 
NMB (Rank)
‘Current’ DAA scenario, mean 
NMB (Rank)
‘Current’ DAAs with IFN/RBV for G3 
mild, mean NMB (Rank)
Ex/non-PWID, mild -3650 (NR) 22,328 (20% prev: 4th, 40% prev: 
4th, 60% prev: 2nd)
18,283 (20% prev: 4th, 40% prev: 
4th, 60% prev: 2nd)
Ex/non PWID, moderate 9404 (20% prev: 3rd, 40% prev: 
3rd, 60% prev: 1st)
29,508 (20% prev: 3rd, 40% prev: 
3rd, 60% prev: 1st)
24,096 (20% prev: 3rd, 40% prev: 
3rd, 60% prev: 1st)
PWID, mild 20% chronic prevalence 59,258 (2) 77,480 (1) 69,942 (1)
PWID, moderate 20% chronic prevalence 60,640 (1) 75,402 (2) 66,621 (2)
PWID, mild 40% chronic prevalence 19,421 (2) 41,989 (2) 35,961 (2)
PWID, moderate 40% chronic prevalence 23,868 (1) 42,816 (1) 36,455 (1)
PWID, mild 60% chronic prevalence -6879 (NR) 18,734 (4) 14,615 (4)
PWID, moderate 60% chronic prevalence -1326 (NR) 20,864 (3) 15,303 (3)
The treatment SVR and duration assumptions for these scenarios can be found in Table 1.
Research Articlegenotypes. Importantly, however, treatment of all groups was
cost-effective (positive NMB) for these scenarios. The increase
in cost-effectiveness of treatment at the mild stage in these sce-
narios was driven by the substantial increase in SVR between the
mild/moderate and cirrhosis stages.
Sensitivity analysis on ‘Future IFN-free DAAs’ treatment scenario
Based on NMB with a £20,000 WTP, the prioritization of patients
for treatment were sensitive to assumptions in a few analyses
(Supplementary Table 2). Variations in cost of DAAs did not
change the relative prioritization rankings, but did alter the
cost-effectiveness of early treatment. If the cost of DAA treatment
was halved or reduced by 75% then treatment of all groups
becomes cost-effective compared to delaying treatment (positive
NMB), though the rankings remain unchanged. Similarly, if DAA
prices reduce by 75% in 10 years, the prioritization rankings
and cost-effectiveness (positive or negative NMB) for each group
remained unchanged, however early treatment of all groups
became slightly less cost-effective compared to delayed treat-
ment at cirrhosis (Supplementary Table 2). This was because
our intervention examined the impact of a 10-year early treat-
ment program (with costs/utilities followed for a total of
50 years), so with early treatment, fewer individuals are treated
later (after 10 years) when prices drop as they have already been
treated earlier with higher priced DAAs. If a shorter (20 year)
time horizon is adopted, then treatment should be delayed (neg-
ative NMB) for all except moderate PWID as few individual ben-
efits are accrued due to the long timescale of liver disease
progression, and if the discount rate is increased to 6% then treat-
ment of ex-non-injectors should be delayed.
Prioritization and ranking were unchanged in relation to dif-
ferent SVRs in PWID (reduced 10% compared to ex-non-PWID)
or in people with cirrhosis (reduced to 85% from 95%). Rankings
were also insensitive to changes in risk behavior after treatment
(e.g., 50% reduction in risk), or varying the average injecting dura-
tion (5 years or 20 years), though greater NMB were achieved in
settings with shorter injecting durations as more infections were
averted despite achieving lower prevalence reductions (results
not shown).
Discussion
Based on NMB alone, which ranked patient groups in terms of
cost of treatment and QALYs gained, PWID with chronic HCV in22 Journal of Hepatology 20the UK (and other sites with <40% chronic HCV among PWID)
would be prioritized ahead of other patients with moderate dis-
ease, after treating people with severe disease, due to the addi-
tional benefit of averting secondary infections. In contrast,
treatment of other patients (non-PWID) with mild disease is unli-
kely to be cost-effective at current HCV drug prices using a will-
ingness to pay (WTP) threshold of £20,000 per QALY compared to
delaying treatment. We estimate that, in sites with a chronic HCV
prevalence of 20% among PWID, treating one person with new
HCV direct-acting antivirals (DAA) prevents more than two other
infections. Treating people with moderate disease earlier (before
cirrhosis) also could avert end stage liver disease (ESLD) and
HCV-related deaths, at a rate of 0.08 (95% CI 0.03–0.17) HCV
deaths per person treated over a fifty year period i.e., for every
13 (6–34) people treated one extra HCV death may be averted.
Our prioritization results were robust to variations in SVR/dura-
tion by genotype and fibrosis stage. Variations in cost of DAAs
did not change the relative prioritization rankings, but did alter
the absolute cost-effectiveness of early treatment, such that
cheaper DAAs increased the cost-effectiveness of treatment, but
a drop in DAA prices in the future made early treatment less
cost-effective.Limitations
Interpretation of our model projections needs to take into
account a number of limitations. First, despite the promise that
new HCV treatments will transform the treatment landscape,
specific parameters related to IFN-free DAA regimens (costs, util-
ities, and health outcomes) are uncertain. The model results were
robust, however, across the scenarios examined, and, although
the decision to delay treatment was preferred (negative NMB)
in some scenarios (influenced by drug cost, time horizon, or
WTP threshold) the relative rankings remained the same
throughout the sensitivity analysis. Therefore, although DAA
costs may reduce in the future, and cost-effectiveness will vary,
the relative prioritization of a treatment at a given time with a
given cost will remain the same regardless of the absolute price.
Second, there are limited data on SVR of IFN-free DAA in dif-
ferent patient groups in real-world settings. Given the uncer-
tainty in SVR rates between earlier disease stages and cirrhosis,
we assumed equal SVR for the base-case scenario which would
not overly favour early treatment. Earlier research suggests that
SVR in PWIDs can be comparable to other patient groups, but16 vol. 65 j 17–25
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these studies are small, focus on the old treatments, and are sub-
ject to selection bias [34]. Reducing SVR for PWID in our model
from 95% to 85% in people with moderate or mild disease, how-
ever, did not alter the ranking of patients for treatment and early
treatment remained cost-effective.
Third, the model assumes that all PWID with chronic infection
are equally likely to be tested and treated, and we did not model
any heterogeneity in transmission risk or access to treatment
among PWID. It is plausible that high risk individuals (who are
at greater risk of transmitting infection to others) are currently
less likely to access HCV treatment than those at lower risk and
therefore, that projections of the prevention benefit of treatment
may be over-estimated. We think such an event, however, is unli-
kely as other analyses have shown that heterogeneity in injecting
risk and treatment uptake has little effect on the model projec-
tions as long as there is minimal movement between populations
of injectors at high and low risk [5].
Fourth, ourmodelwas parameterized to the UK andmay not be
generalizable to low or middle income country settings. In other
countries, the costs and availability of care for each of the HCV dis-
ease stages are likely to vary – for example, in many settings liver
transplantation may not be an option. The health utilities may not
be applicable to other settings, as different populationsmay apply
different weights tomild/moderate disease vs. cirrhosis. Addition-
ally, we did not include HIV-HCV coinfection in the model as coin-
fection rates are low (<1%) in the UK, but many countries have a
high burden of coinfection and this population could have differ-
ent health utilities and health care usage.
Finally, in our model we assumed no transmission occurs
among other (non-PWID) patients and therefore settings where
other routes of transmission (such as iatrogenic transmission)
are common, also may be able to show greater prevention bene-
fits through early treatment of non-PWID who are at risk of trans-
mission [35].
Comparison with existing studies
There is an extensive body of literature examining the cost-
effectiveness of various HCV treatment regimens for PWID incor-
porating individual-level benefits only [8,28,36–43]. Where
examined, most of these analyses conclude it is more cost-
effective to prioritize treatment for those with more advanced
liver disease, as those with mild stage disease may not all other-
wise progress to more severe disease. A recent analysis found
that early DAA treatment at a mild stage (F0 or F1) was not
cost-effective at a $50,000 WTP compared to delay until F2,
assuming a treatment cost of $100,000 [19]. Our analysis simi-
larly found treatment of mild ex/non-PWID was not cost-
effective in contrast to delaying treatment. However, in contrast
we have found substantial benefits in most scenarios for treating
mild PWID due to accrued prevention benefits (which are not
modeled and taken into account by these other studies or recent
NICE appraisals of the new DAA treatments [14]). The 2015 Euro-
pean Association of the Study of the Liver (EASL) Clinical Guide-
lines [44] now recommend that ‘‘treatment should be
prioritized regardless of the fibrosis stage for individuals at risk
of transmitting HCV, including active injection drug users. . .”
but with no supporting evidence for this change in recommenda-
tion since 2014 [17]. Our economic models provide an evidence
base for the guidance but only for populations with low to mod-
erate chronic HCV prevalence among PWID (below 40%).Journal of Hepatology 20Implications
Clinicians and policy-makers face a dilemma. New DAAs offer
highly effective treatments but at a considerable price. In the
UK there are over 100,000 people with chronic HCV, and in the
USA, up to 3 million. With so many patients, and only 5,000 treat-
ments per year in England, even ‘‘cost-effective” treatments will
need to be rationed in order to manage the health budget. The
first priority will be to manage and treat people with severe dis-
ease, which is our baseline strategy. The clinical and policy deci-
sion is then who next to offer treatment to. Delaying treatment
for people with mild disease is an attractive option – but fails
to take account of the prevention benefits of HCV treatment. Clin-
ical decision-making surrounding treatment incorporates numer-
ous factors, including individual, population, ethical and
economic considerations. However, we have shown that from
an economic standpoint, decisions surrounding clinical guidance
should take into account both disease stage and current risk sta-
tus. HCV treatment as a public health prevention strategy, how-
ever, requires treatment scale-up in order to show observable
reductions in HCV prevalence and transmission, which is likely
to happen only once the costs of DAAs are reduced.Financial support
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